? PROJECT 2 There are 2.5 million severe asthma patients in US. These patients are typically unresponsive, or poorly responsive to currently available asthma drugs. Therefore there is high unmet medical need for these patients. Several studies have suggested a central role for IL-17 (also called IL-17A) in severe asthma. Project 2's studies in the Program during Cycle I revealed the importance of IL-17 signaling pathways in the pathogenesis of asthma. The overall goal of Cycle II will focus on developing new therapeutic agents to block IL-17A pathway for the treatment of severe asthma. Project 2 was selected in 2015 to receive NCAI-CC support to begin to advance discoveries into novel therapies for severe asthma. Using IL-17R-deficient mice, Project 2 demonstrated the critical role of IL-17A signaling in High-Fat Diet-induced airway hyperreactivity and Aspergillus-induced animal model of severe asthma. Thus, Project 2 hypothesizes that the IL-17A pathway is an important target for the treatment of severe and steroid-resistant asthma. Through computer-aided virtual screening based on the crystal structure of IL-17RA/IL-17A complex, Project 2 has identified one small molecule lead compound (A18) that inhibits IL-17A binding to IL-17RA in in vitro biochemical assay, in IL-17A- induced gene expression in cultured cells and in preclinical studies, i.e. attenuation of IL-17A-dependent neutrophilia, airway inflammation, and airway hyper-reactivity. Project 2 has also developed a decoy peptide of Act1 (adaptor for IL-17R) to inhibit IL-17A intracellular signaling, and IL17A biomarkers that will facilitate the identification of patient populations responsive to IL-17A inhibitors. Project 2 aims to (1) further optimize the A18 structure for better bioactivities with drug-like properties for a 2nd generation of lead compound(s) and develop peptidomimetics based on the decoy peptides; (2) validate A18, A18 derivatives and peptidomimetics in IL-17A-induced pulmonary neutrophilia, HFD- and Aspergillus-induced severe asthma models in collaboration with Aronica's lab and the Animal Core (Dr. Asosingh); (3) partnering with Novartis, Project 2 will collaborate with Project 1 on defining the Biomarkers for IL-17A-targeted treatment. Additionally, Project 2 will interact with the regulatory experts through Core B for pre-IND advice from the FDA in order to submit the required data for an IND application to move the small molecule development candidate into the clinic. As part of the commercialization plan, Project 2 is enthusiastic to explore the possibility of developing the platform of small molecule and peptidomimetic strategy through the creation of a start-up in Cleveland. Core B will work with Project 2 to identify team members for the start-up with prior life sciences technology start-up experience in order to, raise capital to invest in de-risking the technology to make it more attractive for joint development with a pharma partner or to position the start-up as a competitive acquisition target.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL103453-06
Application #
9146559
Study Section
Special Emphasis Panel (ZHL1-PPG-S (M1))
Program Officer
Noel, Patricia
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
6
Fiscal Year
2016
Total Cost
$788,528
Indirect Cost
$276,302
Name
Cleveland Clinic Lerner
Department
Type
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Herjan, Tomasz; Hong, Lingzi; Bubenik, Jodi et al. (2018) IL-17-receptor-associated adaptor Act1 directly stabilizes mRNAs to mediate IL-17 inflammatory signaling. Nat Immunol 19:354-365
Sweeny, Elizabeth A; Singh, Anuradha Bharara; Chakravarti, Ritu et al. (2018) Glyceraldehyde-3-phosphate dehydrogenase is a chaperone that allocates labile heme in cells. J Biol Chem 293:14557-14568
Reichard, Andrew; Wanner, Nicholas; Stuehr, Eric et al. (2018) Quantification of airway fibrosis in asthma by flow cytometry. Cytometry A 93:952-958
Asosingh, Kewal; Weiss, Kelly; Queisser, Kimberly et al. (2018) Endothelial cells in the innate response to allergens and initiation of atopic asthma. J Clin Invest 128:3116-3128
Reichard, Andrew; Asosingh, Kewal (2018) The role of mitochondria in angiogenesis. Mol Biol Rep :
Yang, Hui; Zhu, Yun; Chen, Xing et al. (2018) Structure of a prokaryotic SEFIR domain reveals two novel SEFIR-SEFIR interaction modes. J Struct Biol 203:81-89
Cai, Gang; Zhu, Liang; Chen, Xing et al. (2018) TRAF4 binds to the juxtamembrane region of EGFR directly and promotes kinase activation. Proc Natl Acad Sci U S A 115:11531-11536
Stober, Vandy P; Johnson, Collin G; Majors, Alana et al. (2017) TNF-stimulated gene 6 promotes formation of hyaluronan-inter-?-inhibitor heavy chain complexes necessary for ozone-induced airway hyperresponsiveness. J Biol Chem 292:20845-20858
Husta, Bryan C; Raoof, Suhail; Erzurum, Serpil et al. (2017) Tracheobronchopathy From Inhaled Corticosteroids. Chest 152:1296-1305
Chen, Jiwang; Sysol, Justin R; Singla, Sunit et al. (2017) Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension. Circulation 135:1532-1546

Showing the most recent 10 out of 136 publications